Street View: Optimistic about launch of Gilead's twice-yearly HIV prevention shot

** Gilead Sciences GILD on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs

** The drugmaker did not disclose sales of Yeztugo, a twice-yearly HIV prevention drug approved by U.S. regulators in June, but CEO Daniel O'Day told Reuters the company is very happy with the launch so far

** Shares up 3.38% to $114.01 in premarket trading

PrEP MARKET RIPE FOR YEZTUGO LAUNCH SUCCESS

** BMO Capital Markets ('Outperform', PT: $130) says co's quarterly results provided 'a breath of fresh air with a clean beat and raise', HIV business was firing on all cylinders

** J.P. Morgan ('Overweight', PT: $135) adds company's comments on Yeztugo launch in PrEP was confident, which points to encouraging launch trends thus far

** Bernstein ('Outperform', PT: $120) notes the PrEP market ripe for Yeztugo launch success

** Oppenheimer ('Outperform', PT: $128) says enthusiasm around PrEP couldn't come at a better time, with favorable Supreme Court ruling requiring health insurers to cover certain recommended preventive services cost-free